{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:21:11Z","timestamp":1762867271155,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.endinu.2019.11.004","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T08:10:01Z","timestamp":1580717401000},"page":"613-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Un caso cl\u00ednico de penfigoide ampolloso inducido por vildagliptina"],"prefix":"10.1016","volume":"67","author":[{"given":"Elena","family":"Gonz\u00e1lez Arn\u00e1iz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Olmos Nieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ariadel Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirian","family":"Alejo Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda D.","family":"Ballesteros Pomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endinu.2019.11.004_bib0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors one due to linagliptin","volume":"232","author":"Ildefonso Mendon\u00e7a","year":"2016","journal-title":"Dermatology"},{"issue":"Suppl. 1","key":"10.1016\/j.endinu.2019.11.004_bib0060","first-page":"S90","article-title":"Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.endinu.2019.11.004_bib0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/fcp.12083","article-title":"Bullous pemphigoid induced by vildagliptin: a report of three cases","volume":"29","author":"B\u00e9n\u00e9","year":"2014","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.endinu.2019.11.004_bib0070","unstructured":"[consultado 17 Jul 2019]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Scientific_Discussion\/human \/000807\/WC500030597.pdf."},{"issue":"8","key":"10.1016\/j.endinu.2019.11.004_bib0075","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care."},{"issue":"2","key":"10.1016\/j.endinu.2019.11.004_bib0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"10.1016\/j.endinu.2019.11.004_bib0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"French Association of Regional PharmacoVigilance Centres Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.endinu.2019.11.004_bib0090","unstructured":"[EMEA] European Medicines Agency. European public assessment report (EPAR) \u2013 Vildagliptina. [consultado 17 Jul 2019]. Disponible en: http:\/\/www.emea.europa.eu."},{"key":"10.1016\/j.endinu.2019.11.004_bib0095","doi-asserted-by":"crossref","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes","author":"Douros","year":"2019","journal-title":"Diabetes Care."},{"issue":"10","key":"10.1016\/j.endinu.2019.11.004_bib0100","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes Estimating the Risk of the New Agents and Characterizing the Patients","volume":"154","author":"Kridin","year":"2018","journal-title":"J JAMA Dermatol."}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016420300033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016420300033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:08:02Z","timestamp":1762866482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016420300033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2530016420300033"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2019.11.004","relation":{},"ISSN":["2530-0164"],"issn-type":[{"type":"print","value":"2530-0164"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Un caso cl\u00ednico de penfigoide ampolloso inducido por vildagliptina","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEEN y SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}